Neurotech International Ltd. · ASX:NTI
Neurotech International — Investor Presentation (June 2021)
18 slides from Neurotech International's investor presentation, Jun 16, 2021
Slide 1: Investor Presentation June 2021
For personal use only I N V E S T O R P R E S E N TAT I O N June 2021 BRIDGING TO A BETTER LIFE • Neurotech International Limited (ASX: NTI)
Slide 2: Disclaimer
Disclaimer For personal use only IMPORTANT INFORMATION Purpose of presentation: This presentation (including this document, any related video or oral These events are, as at the date of this presentation, expected to take place, but there cannot be any presentation, any question and answer session a
Slide 3: Unique Value Proposition
Unique Value Proposition For personal use only $ THC Neurotech is focussed on Neurotech has exclusive worldwide Dolce Cann Global cannabis Potential for the the development & licence to utilise proprietary strains contain naturally low NTI/Dolce cannabis commercialisation of cannabis strains from Do
Slide 4: Corporate Overview
Corporate Overview For personal use only 12-Month Share Price Performance 120 $0.09 CAPITAL STRUCTURE Millions $0.08 Share price 100 $0.054 (as at 15 June 2021) $0.07 80 $0.06 Shares on issue 696m $0.05 60 Options 113m^ $0.04 40 $0.03 Cash at bank ~$4.95m $0.02 20 Market capitalisation ~$38m $0.01 0
Slide 5: Highly Experienced Board
Highly Experienced Board For personal use only Brian Leedman Krista Bates Prof. Allan Cripps AO Mark Davies Winton Willesee Chairman Non-Executive Non-Executive Non-Executive Non-Executive Director Director Director Director • More than 15 years’ • Experienced director of ASX and • Distinguished aca
Slide 6: The device
The device For personal use only 01 02 Proven Complementary Technology & Versatile Mente is world’s first home-based brain Enables clinics, doctors & training therapy that is clinically proven therapists to expand their to increase engagement & improve practice into the home with relaxation in autis
Slide 7: Increased recognition of Mente
Increased recognition of globally For personal use only CE Marking for the Mente device recently Mente therapy referral program adopted renewed, enabling continued marketing by Norcal Brain Center (USA) and & sales of the device in Europe Australasian Neurofeedback Institute (ANFI) Secured Brain The
Slide 8: Medicinal Cannabis industry is only just getting started
Medicinal Cannabis industry is only just getting started For personal use only There are only four approved cannabis based drugs U.S legal marijuana market size, by product type, 2014-2028 (USD Billion FDA • Marinol® (dronabinol) synthetically manufactured (CBD | THC) and registered in the US by the
Slide 9: Global drug market size for neurological disease
Global drug market size for neurological disease For personal use only EPILEPSY MULTIPLE 3$US5.5b SCLEROSIS 1US$20b • Future target • Preclinical studies in TRAUMATIC AUTISM BRAIN INJURY progress SPECTRUM 2US$6.8b DISORDER 5$US2.3b • Future target MIGRAINE 4$1.7b • Pre-clinical completed • Phase I/I
Slide 10: Cannabis strains targeting autism and other neurological disorders
NTI/Dolce strains crop in Griffith, NSW Cannabis strains targeting autism For personal use only and other neurological disorders • Neurotech has an exclusive worldwide license to utilise proprietary cannabis strains from Dolce Cann Global that contain < 0.3% THC for all neurological disorders • Cann
Slide 11: Results from Pre-clinical Studies
Results from Pre-clinical Studies For personal use only Key Findings Studies were designed to assess the In all studies the top DOLCE/NTI strains demonstrated superiority when compared to CBD alone. neuroprotective and • DOLCE/NTI strains demonstrated reduction in brain cell inflammation (up to 60%)
Slide 12: NTI/Dolce strains have unique properties compared to CBD alone
For personal use only NTI/Dolce strains have unique properties compared to CBD alone • Very high levels of CBD-A (primary active) – • Pre-clinical studies have demonstrated that studies have confirmed that CBD-A up to NTI/Dolce strains (<0.3% THC) exhibit 1,000 times more potent in regulating powerf
Slide 13: Expected pathway of cannabis project
Expected pathway of cannabis project For personal use only 1. In vitro assay assessments 2. Product formulation and 3. Phase I/II Human safety Neuronal or muscle cell line assessments final dose profiling & efficacy clinical trials Analytical assessments & To be conducted in Commenced in May 2021 at
Slide 14: Why target Autism Spectrum Disorders (ASD)?
Why target Autism Spectrum Disorders (ASD)? For personal use only • ASD is a serious neuro inflammatory developmental disorder that impairs the ability to communicate and interact • Range and severity of symptoms can vary widely • Common symptoms include; behavioural issues, agitation, repetitive mo
Slide 15: Pathways to commercialisation
Pathways to commercialisation For personal use only The anti-inflammatory properties NTI Dolce strains in combination with minimal presence of THC (< 0.3%) provides three clear pathways to commercialisation: 2. Product formulation and 3. Phase I/II Human safety final dose profiling & efficacy clinic
Slide 16: Strategic Partners
Strategic Partners For personal use only Monash Children’s Hospital A/Prof Michael Fahey – Head of Neurology Professor Katrina Harris – Head of Paediatrics 2. Product formulation and Victorian College of Pharmacy final dose profiling Department: Centre for Medicinal Chemistry ACS Laboratories | Melb
Slide 17: Expected news flow
For personal use only Expected news flow 1. 2. 3. 4. 5. 6. Pre-clinical Further results Interim results Final results Expansion Multi-cohort Phase Expansion of Preclinical Further Preclinical Interim results on Final results on Expansion of Multi-cohort Phase III programme into wider results in MS P
Slide 18: Contact Details
For personal use only • Neurotech International Limited (ASX: NTI) C O N TAC T D E TA I LS Brian Leedman Winton Willesee Chairman Non-Executive Director b.leedman@neurotechinternational.com winton@azc.com.au +61 412 281 780 +61 410 667 844 This presentation has been authorised for release by the Cha
Neurotech International — Investor Presentation (June 2021) on 6ix